Investors

Overview

CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. CTI BioPharma has a commercial presence in Europe and a late-stage development pipeline, including pacritinib, CTI BioPharma’s lead product candidate, which is currently being studied in a Phase 3 program for the treatment of patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington, with offices in London and Milan under the name CTI Life Sciences Limited. Our management and investor relations team provide updates throughout the year through conference calls, investor events, press releases and SEC filings. We invite you to sign up for our investor alerts and listen to our archived and live presentations.

To CTI’s knowledge, all press releases, scientific papers and abstracts, and the information contained within them were timely and accurate when issued. The continued accuracy of this material beyond the date of issuance and posting on the website is not assured. CTI has no intention of updating this information and specifically disclaims any duty to do so. These documents may contain forward-looking statements. Actual results could vary dramatically as a result of known and unknown risks and uncertainties. Please see Terms of Use for this website.

IR Contact

 
  • Current Quote
  • Stock Chart
NASDAQ:CTIC
$0.49 + 0.04 (11.36%)
Day High:$0.58
Day Low:$0.45
Volume:6,833,262
12/02/164:00 p.m. ET
Delayed at least 15 minutes.

Ed Bell
T +1 206-272-4345
invest@ctibiopharma.com


 

Recent News

MORE
DateTitle 
Dec 01, 2016CTI BioPharma Presents Nonclinical Pharmacology Study Demonstrating Pacritinib Has Distinct Profile Amongst JAK Inhibitors At EORTC-NCI-AACR Molecular Targets And Cancer Therapeutics Symposium
SEATTLE, Dec. 1, 2016 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced the results of a translational pharmacology study comparing biomarker activity profiles for three JAK inhibitors: pacritinib, ruxolitinib and momelotinib, using the BioMAP® Diversity PLUS panel of in vitro human primary cell-based systems. The results demonstrated distinct profiles amongst these JAK inhibitors and suggest that clinical responses are likely to be distinct with each age... 
Printer Friendly Version
Nov 21, 2016CTI BioPharma Announces Phase 3 Data from the PERSIST-2 Trial of Pacritinib to be Presented in Late-Breaking Session at ASH Annual Meeting
SEATTLE, Nov. 21, 2016 /PRNewswire/ -- CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) today announced that data from the randomized Phase 3 PERSIST-2 clinical trial comparing the investigational agent pacritinib, an oral multikinase inhibitor, with physician-specified best available therapy (BAT), including ruxolitinib, for treatment of patients with myelofibrosis whose baseline platelet counts are less than 100,000 per microliter will be presented in a late-breaking oral presentation at the u... 
Printer Friendly Version
Nov 08, 2016CTI BioPharma Reports Third Quarter 2016 Financial Results
SEATTLE, Nov. 8, 2016 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA:CTIC) today reported financial results for the third quarter ended September 30, 2016. "We recently reported top-line data from our second Phase 3 trial of pacritinib and are encouraged by its clinical profile, particularly in patients with severe thrombocytopenia, and look forward to the presentation of the full results at an upcoming scientific meeting," said Richard Love, Interim President and CEO of CTI BioPharma. "... 
Printer Friendly Version

Events

MORE
There are no past events to display.
Data provided by Nasdaq. Minimum 15 minutes delayed.